INTRODUCTION
============

Vascular smooth muscle cell (VSMC) growth plays a critical role in different pathological conditions such as atherosclerosis \[[@B1]\] and its clinical complications. Indeed, development of these vascular diseases is associated with a loss of vascular contractility counterbalanced by an increase of VSMC migration, proliferation, matrix secretion, and, in some cases, hypertrophy \[[@B2]\]. Different agonists modulate VSMC phenotype and activities in the vessel wall. For example, platelet-derived-growth factor (PDGF), particularly PDGF-BB, stimulates both proliferation and migration \[[@B3]\]. AngiotensinII (AngII), the active biological peptide of the renin-angiotensin system, has potent vasoconstrictor actions and is directly involved in the development of hypertension. AngII induces a multitude of signalling pathways which, depending on the VSMC phenotype, can lead to contraction, hyperplasia, or hypertrophy \[[@B4], [@B5]\]. Many transcription factors (such as c-fos \[[@B6]\], Ets-1 \[[@B7]\], NF*κ*B \[[@B8]\]) and the subsequent expression of a large number of genes (eg, alpha-actin, Collagen IV, MCP-1, Endothelin-1, PDGF-A, TSP-1, bFGF, and PDGF A-chain \[[@B9]\]) are stimulated by AngII. However, the molecular mechanisms controlling gene transcription during these processes remain at this stage poorly understood.

A new gene (6A3-5/Osa2), which is overexpressed in proliferating, rat aortic VSMC, was initially identified by differential display \[[@B10]\]. This partially cloned gene of 1.2 kb, not referenced in Genbank, shares sequences homologies with the ARID (AT-rich interaction domain) transcription modulator family. ARID-containing proteins are involved in the control of transcription during cell growth and embryonic development \[[@B11], [@B12]\]. However, their precise functions are not fully understood. In the current study, we have cloned the full-length rat 6A3-5/Osa2 cDNA and characterized its deduced protein sequence as a member of the ARID family. Moreover, the knock-down of 6A3-5/Osa2 expression, which is overexpressed in PDGF-dose and time-dependant manner, resulted in a significant reduction of VSMC proliferation. In vivo work showed that 6A3-5/Osa2 is overexpressed in SMC of aortas derived from hypertensive (Lyon hypertensive, LH) but not normotensive (Lyon low-blood pressure, LL) rats. The 6A3-5/Osa2-gene expression is downregulated by an ACE inhibitor and upregulated by exogenous AngII in hypertensive rats.

MATERIALS AND METHODS
=====================

Isolation of a full-length 6A3-5 rat cDNA
-----------------------------------------

A 6A3-5 full-length cDNA was cloned by screening a rat foetal brain cDNA library (Origene Technologies, Inc) using primers generated from a previously derived partial sequence (Genbank accession number: AJ005202) \[[@B10]\], combined with in silico analysis of genome databases. BlastA (NCBI) and multiple alignments performed using ClustalW (EBI) were used for assessing sequence homologies.

Cell culture
------------

Primary human and rat VSMC were cultured as previously described \[[@B13]\]. VSMC, at 80% of confluence, were serum starved for 48 h and stimulated by PDGF-BB. Dose-effect (0 to 20 ng/ml) and time-response (0, 2, 4, 8, or 24 h) experiments were performed on human VSMC. Following treatment, VSMC are harvested in Trizol or in lysis buffer (1% of 10 mM aprotinin, 10 mM leupeptine, 10 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride, 25 mM Tris pH 7.6, 150 mM NaCl, and 1% Triton X100).

Immunofluorescence
------------------

After fixation and permeabilization (100% methanol at −20°C during 5 min), nonspecific sites were blocked (PBS/3%BSA) for 1 hour at 25°C. The primary antibody (6H3 anti-Osa2 hybridoma supernatant (1 : 5) \[[@B14]\], mouse anti-*α*-actin monoclonal antibody (1 : 100) or a rabbit anti-NFKB polyclonal antibody (1 : 100), Dako) was incubated for 2 hours at 25°C. After 3 washing steps, VSMC were incubated in the blocking solution with an appropriate secondary antibody-FITC-conjugated (Dako) for 1 hour at 37°C. After 4 washing steps, coverslips were mounted and analysed by fluorescence microscopy.

Northern blot
-------------

Total RNA was isolated according to the Trizol procedure. Northerns were performed as previously described \[[@B15]\]. The abundance of 6A3-5/Osa2 mRNA was normalized with respect to 18 S rRNA and the ratio expressed in arbitrary units (au).

Western blot
------------

Nitrocellulose membrane bearing electrotransfered proteins (30 **μ**g), separated on 7% SDS-polyacrylamide gels, were blocked for 4 hours at 37°C with TBS/ 0.05% Tween20/3% gelatine, and incubated overnight at 4°C with an anti-Osa2 antibody (6H3, 1 : 5 \[[@B14]\]). A swine anti-mouse antibody, conjugated to horseradish peroxidase (Bio-Rad), was then used with a chemiluminescent technique (ECL kit™, *Amersham*). Expression level of 6A3-5/Osa2 protein was estimated by Quantity One tool (Bio-Rad) and normalized with Coomassie blue staining.

Gene knock-down by antisense oligonucleotides
---------------------------------------------

The sequences and locations of the generated oligonucleotides targeted against human Osa2 cDNA AF468300 are summarized in [Table 1](#T1){ref-type="table"}. For transfection experiments, VSMC at 60--70% of confluence were serum-starved for 48 h and then incubated with 25--200 nM ODN at concentration in serum- and antibiotic-free MEM medium in the presence of oligofectamine (Invitrogen). After 4 hours, VSMC were stimulated by PDGF (20 ng/ml) for different periods of time (0, 2, 4, 6, and 24 h) and then harvested in a cell lysis buffer or Trizol. Alternatively, after transfection, VSMC were stimulated by PDGF for 24 hours and used for Bromodeoxyuridine incorporation test (Roche) to estimate cell proliferation.

Animal studies
--------------

Protocols for animals\' (Lyon hypertensive (LH) and Lyon low-blood pressure (LL) strains) housing and treatment have been previously detailed \[[@B16]\]. Three groups were used: the first group (controls, *n* = 8) was untreated and used as controls. The second group (Ace I, *n* = 8) was treated with an ACE inhibitor, perindopril (3 mg/kg/d), for 4 weeks. The third group (Ace I+ANGII, *n* = 8) was treated with an ACE inhibitor, perindopril (3 mg/kg/d) and perfused subcutaneously with AngII (200 ng/kg/min) for 4 weeks.

Quantification of 6A3-5/Osa2 mRNA by quantitative-PCR
-----------------------------------------------------

Frozen rat aortas were homogenized at 0°C in 500 *μ*l Trizol and total RNA isolated. Reverse transcription product (Superscript II, *Invitrogen*) was used for quantitative real-time PCR (Q-PCR) on an ABIPrism 7900. Q-PCR assay was carried out using the Assay-on-Demand for 6A3-5, calponin, SM22-alpha, and 18 S mRNA levels were using the comparative Ct method.

Immunohistochemistry
--------------------

Immunohistochemistry was performed on frozen aorta sections (5 *μ*m) fixed in acetone as previously described \[[@B15]\] with an anti-Osa2 hybridoma supernatant (6H3) \[[@B14]\] or an anti-*α*-actin (Dako) monoclonal antibody. Primary antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase followed by 3-amino-9-ethylcarbazole (Dako). The specific location of the *α*-actin in the media of aorta was used to define the medial boundaries. The media thickness was then measured at a magnification of X40 in slides counterstained with Haematoxylin (Dako).

RESULTS
=======

Cloning of full-length rat 6A3-5 cDNA
-------------------------------------

The cloned gene has a 6569 bp cDNA sequence (GenBank accession number: AJ440711) and a deduced amino acid sequence corresponding to a 5276 bp open-reading frame ([Figure 1(a)](#F1){ref-type="fig"}). The cDNA contained 1268 bp in the 3′-untranslated region; the 5′-untranslated sequence is not totally cloned. The putative 1758 amino acid 6A3-5 protein has an expected molecular weight of 180 kDa and bears four conserved motifs ([Figure 1(b)](#F1){ref-type="fig"}). The first motif is a DNA binding domain, called AT-rich interaction domain or ARID, located in the N-terminal half (aa 568 to 672). Two other motifs comprising evolutionary conserved domains known as OHD (Osa Homology Domain)-1 (aa 1114 to 1200) and OHD2 (aa 1437 to 1758) are present within the *C*-terminal half of the protein. These three motifs are the signature of a novel family of transcription modulators called Osa family and indicate that 6A3-5 is the rat Osa2 homologue. Finally, a fourth motif represented by a nuclear localization signal is also present in the *C*-terminal of 6A3-5/Osa2 sequence suggesting a nuclear localization of this protein that was subsequently confirmed.

Multiple sequence alignment and homologies to rat 6A3-5/Osa2
------------------------------------------------------------

Protein similarity searches revealed two subgroups with significant homologies to rat 6A3-5/Osa2 protein. The 1st subgroup comprises proteins bearing ARID, OHD1, and OHD2 functional domains. This group shows a remarkably high degree of conservation of amino acid sequences, and includes the recently cloned human Osa2 \[[@B14]\]. This protein appears to be the human orthologue of rat 6A3-5/Osa2, mouse, and human Osa1 \[[@B17]\], *Drosophila* Osa/eyelid \[[@B18]\] and yeast SWI1 protein \[[@B19]\] ([Figure 2](#F2){ref-type="fig"}). The 2nd subgroup shows homologies that are limited to the ARID domain and include *Drosophila* dead-ringer protein \[[@B20]\], its homologues in mouse (bright) \[[@B21]\] and human (DRIL-1), mouse Mrf2 \[[@B22]\], and the murine and human jumonji proteins ([Table 2](#T2){ref-type="table"}).

Cellular localization
---------------------

VSMC characterized with anti-*α*-actin antibody showed its nucleus to be equally labelled with an anti 6A3-5/Osa2 \[[@B14]\] or an anti-NFKB antibody. Negative controls showed no labelling ([Figure 3](#F3){ref-type="fig"}).

6A3-5 expression in different phenotype of vascular SMC
-------------------------------------------------------

Transcription levels of 6A3-5/Osa2 and *α*-actin markers were measured after dedifferentiation of ex vivo SMCs from a contractile (passage 0, P0) to an in vitro synthetic phenotype (passage 9, P9). Northern-blots showed that 6A3-5 is upregulated by 3-fold (*n* = 3) in the synthetic phenotype in comparison to the contractile quiescent phenotype. In contrast, *α*-actin expression is present in the contractile SMCs phenotype and lost on differentiation to a synthetic phenotype ([Figure 4(a)](#F4){ref-type="fig"} and data not shown) \[[@B23]\]. The 6A3-5/Osa2 gene was significantly upregulated in a smooth muscle cell line (V8) that was observed to be highly proliferating \[[@B24]\] compared with secretory/ synthetic cells (results not shown).

Time course and dose effect of PDGF on 6A3-5/Osa2 in VSMC
---------------------------------------------------------

Human and rat (data not shown) VSMC were serum starved, inducing a down-regulation of 6A3-5/Osa2 mRNA expression levels, and then treated with 20 ng/ml of PDGF-BB for 0, 2, 4, 8, and 24 hours. Northern blot analysis showed that the levels of 6A3-5/Osa2 mRNA reached a peak at 2 hours and remained above the control level for at least 24 hours after PDGF treatment ([Figure 5(a)](#F5){ref-type="fig"}). In addition, a PDGF dose-dependant effect was also observed with a maximal increase achieved at 20 ng/ml ([Figure 5(b)](#F5){ref-type="fig"}). Similar results were observed at 4 hours, by Western blot, for 6A3-5/Osa2-protein expression (Figures [5(c)](#F5){ref-type="fig"}, [5(d)](#F5){ref-type="fig"}).

Antisense ODN inhibition of 6A3-5/Osa2 expression and VSMC proliferation
------------------------------------------------------------------------

A series of 20-base phosphorothioate antisense ODN ([Table 1](#T1){ref-type="table"}, ODN~AS1-4~) was screened for its ability to selectively inhibit 6A3-5/Osa2 protein expression in human VSMC. After transfection, VSMC were stimulated by PDGF-BB for 4 hours. The ODN~AS3~, which hybridizes to the 6A3-5/Osa2 ATG translation initiation site, showed a significant inhibition of 6A3-5/Osa2 mRNA and protein expression in comparison to its sense, scrambled, and mismatched controls (Figures [6(a)](#F6){ref-type="fig"}, [6(b)](#F6){ref-type="fig"}, [6(c)](#F6){ref-type="fig"}). Moreover, treatment of human VSMC with increasing concentrations of ODN~AS3~ (25, 100, 200 nM) resulted in a dose-dependent reduction in 6A3-5/Osa2 protein level ([Figure 6(d)](#F6){ref-type="fig"}) but had no effect on P53 expression. Indeed, 6A3-5/Osa2 expression is reduced by 60--70% in presence of 200 nM of antisense ODN~AS3~.

To investigate whether reduction of 6A3-5/Osa2 expression affected PDGF-induced proliferation, serum starved human VSMC were exposed to ODN~AS3~ and then stimulated by PDGF-BB for 24 hours. ODN~AS3~ reduced by 50--60% PDGF-induced proliferation in human VSMC ([Figure 7(a)](#F7){ref-type="fig"}) while sense, scrambled, or mismatched oligonucleotides derived from ODN~AS3~ had no effect. Moreover, increasing the concentration of ODN~AS3~ significantly reduced PDGF-induced proliferation of VSMC in a dose-dependent manner ([Figure 7(b)](#F7){ref-type="fig"}).

Expression of 6A3-5/Osa2 and vascular Phenotype in LH versus LL rats
--------------------------------------------------------------------

Quantitative PCR performed on aorta excised from hypertensive (LH) rats exhibited significantly increased 6A3-5/Osa2 gene expression levels compared to those present in normotensive (LL) rats ([Figure 8(a)](#F8){ref-type="fig"}). A significant decrease in VSMC contractile markers, calponin and SM22-alpha, was observed in LH but not LL rats (Figures [8(b)](#F8){ref-type="fig"}, [8(c)](#F8){ref-type="fig"}).

Immunolabelling indicated the presence of 6A3-5/Osa2 in VSMC of LH and LL aortas (Figures [9(a)](#F9){ref-type="fig"}, [9(b)](#F9){ref-type="fig"}), but no labelling was observed in negative controls ([Figure 9(e)](#F9){ref-type="fig"}). Interestingly, the 6A3-5/Osa2 antibody shows similar labelling to those observed with proto-oncogene c-fos (Figures [9(c)](#F9){ref-type="fig"}, [9(d)](#F9){ref-type="fig"}). Such an increased level of 6A3-5/Osa2 was associated with a state of hypertension. Indeed, work by Aguilar et al \[[@B16]\] has shown that LH rats have a systolic blood pressure (SBP) of 166 ± 3.59 compared to 131 ± 2.78 mmHg for LL.

Expression of 6A3-5/Osa2 and vascular phenotype in ACE inhibitor treated LH and LL rats
---------------------------------------------------------------------------------------

Four-week treatment with Perindopril (an ACE inhibitor) significantly reduced SBP in both LH (from 166 ± 3.59 to 134 ± 1.84 mmHg) and LL (from 131 ± 2.78 to 104 ± 2.39 mmHg) compared to untreated animals \[[@B16]\]. Interestingly, the 6A3-5/Osa2-gene expression level decreased in treated LH, but not LL, rats ([Figure 10(a)](#F10){ref-type="fig"}). Moreover, VSMC contractile markers showed, by Q-PCR, a decrease in calponin and SM22-alpha in both LH and LL animals (Figures [10(b)](#F10){ref-type="fig"}, [10(c)](#F10){ref-type="fig"}). However, Vessel wall media thickness in LH and LL was not affected by such a treatment ([Figure 11(c)](#F11){ref-type="fig"}).

Expression of 6A3-5/Osa2 and vascular phenotype in AngiotensinII-perfused LH and LL rats
----------------------------------------------------------------------------------------

Perindopril treatment, of the 2 strains, was followed by chronic perfusion of AngII which showed, over a period of 4 weeks, an increase of SBP in LH (from 134 ± 1.84 to 231 ± 5.67 mmHg) and a steady SBP (from 104 ± 2.39 to 192 ± 5.46 mmHg) in LL rats \[[@B16]\]. AngII induces a significant upregulation of aortic 6A3-5/Osa2 excised from hypertensive (LH) rats in comparison to their unperfused controls ([Figure 10(a)](#F10){ref-type="fig"}). Moreover, decrease in VSMC contractile markers, closely followed the hypertrophy state of the vessel wall in these two strains (Figures [10(b)](#F10){ref-type="fig"}, [10(c)](#F10){ref-type="fig"}). In contrast, aortic 6A3-5/Osa2-gene expression was not modified in normotensive (LL) rats. One should note that AngII perfusion induced a significant aortic media hypertrophy in LH ([Figure 11(c)](#F11){ref-type="fig"}) and to a much lesser extent in LL rats in comparison to their unperfused controls ([Figure 11(c)](#F11){ref-type="fig"}).

DISCUSSION
==========

This study reports the cloning and the characterization of a new gene (6A3-5/Osa2) overexpressed in proliferating rat vascular smooth muscle cells. Several lines of evidence show that this new gene is an early-gene activator that may be implicated in the control of VSMC activities.

6A3-5/Osa2 protein bears a DNA binding motif called ARID and two recently described conserved motifs, OHD1 and OHD2. These functional domains define the recently described Osa family of transcription modulator. Recently, Hurlstone et al \[[@B14]\] cloned the human homologue of 6A3-5 and showed that the OHD2 motif is necessary for binding BRG-1 (Brahma-related gene-1), a key catalytic component of the SWI/SNF-A chromatin remodelling complex. In contrast to other ARID proteins, Osa proteins show no sequence preference for AT rich sites. Nonetheless, work using *Drosophila* suggest that Osa proteins may participate in targeting SWI/SNF to a subset of promoters in vivo and induce the activation or repression of target gene expression. Prior to our study, no Osa protein had been described in vascular cells, and very little is known about the function of these proteins in mammals.

In this study, we have observed, in a similar way to c-fos, an early upregulation of 6A3-5/Osa2 soon after mitogenic stimulation of human or rat VSMC by PDGF-BB. Increased activity of the PDGF signalling pathway has been implicated as a contributing factor in the progression of atherosclerosis or restenosis. PDGF induces activation and phosphorylation of several cytosolic signalling molecules and nuclear transcription factors, including Egr-1 (early growth response-1), Ets-1, *c-fos*, and *c-jun*, which stimulate expression of their target genes. These data indicate that 6A3-5/Osa2 is an early PDGF-responding gene potentially implicated in VSMC proliferation. To validate this hypothesis, we generated four specific sets of ODN antisense directed against 6A3-5/Osa2. Only one of these, ODN3, is able to inhibit 6A3-5/Osa2 expression at the mRNA and the protein level in dose and sequence-dependant manner. It is interesting to note that ODN3 targets the ATG initiation site. Previous studies have demonstrated that such targeting is very effective in inhibiting gene expression by antisense phosphorothioate oligonucleotides. Indeed, ODN controls used in the present study indicated that 6A3-5/Osa2 RNA and protein depletion was due to a sequence-specific antisense effect, as neither the sense nor the scrambled or mismatched control ODNs caused 6A3-5/Osa2 depletion. Moreover, we observed no effect on p53 gene expression following Osa2 inhibition, suggesting that ODN~AS~ inhibit selectively 6A3-5 expression. We then used ODN3 in association with BrdU incorporation assays to assess the role of 6A3-5/Osa2 in VSMC proliferation. ODN3 antisense was able to significantly reduce proliferation of PDGF-stimulated VSMC in a dose and sequence-dependent manner. Recently, Watanabe et al \[[@B22]\] produced the first evidence that an ARID protein family member is implicated in differentiation and control of VSMC proliferation. Their study showed that overexpression of Mrf2 induces expression of specific smooth muscle marker, such as alpha-actin and SM-22alpha. Interestingly, in contrast to 6A3-5/Osa2, Mrf2 retarded cellular proliferation. It is interesting to note that Mrf-2 binds a specific DNA sequence (AATA(C/T)) in contrast to Osa proteins. The apparent functional divergence in regard to cellular proliferation between the two ARID-bearing proteins could be linked to different properties of their DNA binding activities. The mechanism by which 6A3-5/Osa2 influences cell proliferation is unknown. However, human Osa2 was recently shown, to stimulate transcription as a cofactor of glucocorticoid receptor-dependent transcriptional activation in cultured mammalian cells \[[@B25]\]. Interestingly, glucocorticoids are known to modulate proliferation and expression of some target genes in VSMC (such as I*κ*B, NaKATPase, adrenomedullin). Further investigation will be necessary to investigate by which molecular mechanisms, that is, by which target genes 6A3-5/Osa2 influences VSMC proliferation.

In a similar way to PDGF, we have previously observed an early upregulation of 6A3-5/Osa2 in cultured rat VSMC in response to AngII \[[@B15]\]. Several signalling responses are shared between PDGF and AngII activation. Indeed, AngII stimulation of VSMC is associated, in a similar manner to PDGF, with an upregulation of early activated genes such as c-fos and c-myc and growth factors such as PDGF and bFGF \[[@B9]\]. ACE inhibition by perindopril induces a reduction of c-fos and c-jun expression in response to balloon injury \[[@B26]\]. In vitro study has shown a link between AngII receptor and PDGF*β* receptor in cultured VSMC \[[@B27]\]. Moreover, AngII has recently been reported to transactivate the PDGF*β* receptor by cross-talk in stroke-prone SHR rats by comparison, Wistar-Kyoto rats their normotensive controls, did not show this effect \[[@B28]\]. In this study, hypertensive rats (LH) had significantly higher aortic 6A3-5/Osa2 gene expression levels in comparison to normotensive rats (LL). Moreover, while perindopril treatment reduced blood pressure in these 2 strains, it only affected 6A3-5/Osa2-gene expression in LH but not LL. Finally, exogenous AngII perfusion in the presence of ACE inhibitor increased blood pressure levels in both strains but increased 6A3-5/Osa2-gene expression only in LH but not LL. Interestingly, Kim et al \[[@B28]\] have reported that treatment of SHR rats with perindopril significantly reduced aortic PDGF-*β* receptor phosphorylation and ERKinase activity which is restored by chronic (but not acute) infusion of AngII. It is known that PDGF*β* receptor is chronically activated in SHR compared to Wistar-Kyoto rats.

While LH rats present a higher blood pressure than LL rats, similar levels of plasma AngII were reported \[[@B29]\]. Interestingly, results by Lantelme et al \[[@B30]\], have shown that inhibition of the renin-angiotensinII system in newborn LH rats prevents the development of hypertension. It is conceivable that VSMC of LH rats are very much more sensitive to AngII compared to LL. Such hypersensitivity has been reported for VSMC, isolated from SHR rats, which show abnormal growth in vitro with accelerated entry into S phase of cell cycle and increased cdk2 activity in comparison to VSMC from Wistar-Kyoto rats \[[@B31]\]. Aortic gene expression of 6A3-5/Osa2 is significantly increased in LH compared to LL rats. Such enhanced expression of 6A3-5/Osa2 gene in LH rats may be linked to the potential hypersensitivity of the VSMC that not only results in increased blood pressure but modified phenotype gene markers and media hypertrophy. On treatment with an ACE inhibitor, LH rats show a significant reduction in aortic 6A3-5/Osa2 expression, not observed in LL rats, that is presumably due to the hypersensitivity of the VSMC to AngII. Chronic perfusion of AngII, in the presence of an ACE inhibitor, induces a significant increase in 6A3-5/Osa2 expression in LH but not in LL rats. Sabri et al \[[@B32]\], have shown that AngII perfusion induces a reversion of VSMC to an immature phenotype. Similarily to AngII, PDGF under in vitro conditions induces suppression of smooth muscle-specific gene (□-actin and SM22alpha) through activation of Pi3K/Akt signalling pathways and subcellular redistribution of serum response factor \[[@B33]\]. One should also note that higher glucocorticoid plasma levels are observed in LH strains in response to AngII \[[@B16]\]. As previously indicated, 6A3-5/Osa2 has been implicated as a cofactor of glucocorticoid receptor-dependent transcription \[[@B25]\]. The overall data in this study strongly suggests that the potential hypersensitivity of VSMC, in LH rats, not only controls blood pressure levels but also 6A3-5/Osa2 expression, gene markers of VSMC phenotype, and media hypertrophy.
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Figures and Tables
==================

###### 

*Full-length ORF sequence of rat 6A3-5, 6569 pb*. (a) The full-length rat 6A3-5 cDNA has a first methionine that corresponds to an ATG codon (position 25 underlined) and a stop codon (TGA, position 5301) followed by polyadenylation signal (position 6299). (b) ORF translation sequence with 1758 aa. Conserved motifs are indicated: ARID motif (568--672) is underlined, OHD motifs (OHD1: 1114-1200; OHD2: 1437--1758) are boxed, and NLS (nuclear localization signal) (1352--1369) in bold.
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*Alignments of conserved domains of ARID proteins by CLUSTALW program*. (a) ARID motif alignment among different species is shown. (b) OHD-1 (Osa hoomology domain-1) motif alignment. (c) OHD-2 (Osa hoomology domain-1) motif alignment. Conserved aa residues are shown by underlining. Identical residues are indicated in grey. H: human, r: rat, M: Mouse, d: Drosophila, Y: yeast (hELD/OSA1 or hOsa2: human homolog of 6A3-5/Osa2).
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![*6A3-5/Osa2 cellular localization on VSMC*. Actin was used as a cytoplasmic control of smooth muscle cells marker, while NFKB served as a nuclear control. Cell nucleus was labelled with an anti-6A3-5/Osa2 or an anti-NFKB antibody in comparison to isotype control (mouse IgG).](JBB2006-97287.003){#F3}
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*6A3-5 and *α*-actin SMC expression in different vascular SMC*. (a) Levels of 6A3-5 gene transcription were compared, by northern blot, between the contractile (passage 0, P0) and the secretory/synthetic phenotype (9th passage, P9). Phenotypes were characterized by the *α*-actin SMC marker. The 18 S served as a control for loading and quantification. (b) Quantification of 6A3-5 signals, done on 3 independent northern blots, reported to the 18 S levels. Results show 6A3-5 mRNA levels to be increased by 3 folds in synthetic cells compared to contractile cells.

![](JBB2006-97287.004a)

![](JBB2006-97287.004b)

###### 

*Time course and dose effect of PDGF on 6A3-5/Osa2 expression*. (a) Time course of 6A3-5/Osa2 mRNA level analysed by Northern-blot, following treatment of human proliferating VSMC (9th passage) with 20 ng/ml PDGF. VSMC were serum starved for 48 hours before analysis. (b) Dose effect of 6A3-5/Osa2 mRNA level analysed by Northern-blot, following treatment of VSMC with increasing concentrations of PDGF for 2 hours. (c) Time course of 6A3-5/Osa2 protein levels investigated by Western blot. (d) Dose effect of 6A3-5/Osa2 protein levels investigated by Western blot, following VSMC treatment with increasing concentrations of PDGF for 4 hours. The results are representative of three independent experiments. Northern-blots were quantified by Quantity One tool (Bio-Rad) and normalized by 18 S rRNA level. Data are presented as means ± SEM.\* : *P* \< .05 versus nonstimulated control cells. The Coomassie blue-stained gel indicates equal protein loading.
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###### 

Inhibition of 6A3-5/Osa2 expression by ODN3 antisense. (a) Western blot of 6A3-5/Osa2 protein expression, following 4 hours of PDGF-BB stimulation. Serum starved VSMC (0) were treated, first, by 6A3-5/Osa2-ODN3 sense (S), antisense (AS), mismatched (Mis), scrambled (Scr), or vehicle (NT) at 200 nM. (b) Northern blot of 6A3-5/Osa2 mRNA expression, following 4 hours of PDGF-BB stimulation. (c) Quantification of Northern blot results, which are representative of three independent experiments. (d) Western blot of 6A3-5/Osa2 protein expression, following 4 hours of PDGF-BB stimulation. Serum starved VSMC (0) were treated, first, by 6A3-5/Osa2-ODN3 sense or antisense at different concentrations (25, 100, and 200 nM).
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###### 

*Inhibition of PDGF-stimulated VSMC proliferation by antisense ODN3*. (a) Serum starved VSMC were treated by ODN3 sense, antisense, mismatched, and scrambled oligos at 200 nM followed by PDGF-BB (20 ng/ml) stimulation for 0 or 24 hours in presence of BrdU. (b) Serum starved VSMC were treated by ODN3 sense and antisense (at 50, 100, or 200 nM) following 0 and 24 hours of PDGF-BB (20 ng/ml) stimulation. Untreated VSMC are used as controls of proliferation rate. The results are representative of four independent experiments. Data are presented as means ± SEM.\* : *P* \< .05 versus nontransfected cells (NT).
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###### 

*Expression of 6A3-5/Osa2 and vascular phenotype in LH versus LL rats*. (a) 6A3-5/Osa2 aortic mRNA expression is significantly higher in hypertensive (LH) compared to normotensive (LL) rats. (b) Calponin (VSMC contractile phenotype marker) aortic mRNA gene expression is significantly reduced in LH versus LL rats. (c) SM22 alpha (VSMC contractile phenotype marker) aortic mRNA gene expression is significantly reduced in LH versus LL rats. Results are indicated as a ratio of mRNA expression in comparison to 18 S expression. Data are presented as means ± SEM.\* : *P* \< .05 versus LL normotensive rats.
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###### 

*Localization of 6A3-5/Osa2 in aortas from LH and LL rats*. (a) 6A3-5/Osa2 labelling is observed in SMC of the inner media from AngII-perfused LH rats (X40). (b) 6A3-5/Osa2 labelling is observed in SMC of the inner media from AngII-perfused LL rats. (c) c-fos antibody showed a similar localization to 6A3-5/Osa2 in LH rats. (d) c-fos antibody showed a similar localization to 6A3-5/Osa2 in LL rats. (e) Negative control showed no labelling. Similar localization and labelling was observed for 6A3-5/Osa2 for all tested aortas (data not shown).
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*Expression of 6A3-5/Osa2 and vascular phenotype in ACE inhibitor treated LH and LL rats*. (a) 6A3-5/Osa2 aortic mRNA expression in untreated LH and LL rats (controls) was compared to ACE inhibitor treated rats in the absence (Ace I) or presence of perfused ANGII (Ace I + ANGII). 6A3-5/Osa2 gene expression is downregulated by the ACE inhibitor and upregulated by exogenous AngiotensinII in LH rats. (b) Calponin gene expressions were quantified in these same animals. (c) SM22 alpha gene expressions were also quantified in these same animals. Results are indicated as a ratio of 6A3-5/Osa2 mRNA expression in comparison to 18 S expression. Data are presented as means ±SEM.\* : *P* \< .05 versus controls untreated rats, for each strain.
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###### 

*Analysis of media hypertrophy*. Media thickness was determined, following haematoxylin/eosin staining of aorta sections. (a) Control LH rats were studied for their media thickness. (b) AceI treated LH rats were also analysed. (c) AceI and ANGII treated LH rats. (d) Control LL rats. (e) AceI treated LL rats. (f) AceI + ANGII treated LL rats. (g) Quantification of the above data is presented as means ± SEM\* : *P* \< .05 versus controls for each strain. ^\#^ : *P* \< 0.05 versus normotensive controls rats, ^𝒸^ : *P* \< .05 versus AngII-perfused normotensive rats.
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###### 

Homologies of rat 6A3-5 sequences with ARID proteins. Homologues are divided into two subgroups. The first subgroup, which would define the subfamily called Osa, has members bearing an ARID motif and two OHD domains. The second subgroup indicates different ARID proteins.

  ------------------------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------- ----------------------------------------------------- ----------------------------
                                                                            Species                                                                       Yeast                             Drosophila                                                 Mouse                                                 Human
                                                                                                                                                                                                                                                                                                             
  Subgroup 1                                                                Names                                                                         Swi1                              Osa, *eyelid*                                              Osa1                                                  Osa1, *P270, B120, BAF250*
                                                                                                                                                                                                                                                                                                             
  Accesion no                                                               M84390                                                                        AF053091                          AF268912                                                   AF521670                                              
  Chromosome no                                                             ---                                                                           3                                 4                                                          1p35-p36                                              
  cDNA Length                                                               3027 bp                                                                       10601 bp                          7041 bp                                                    6418 bp                                               
  Protein Length                                                            825 aa                                                                        2715 aa                           1902 aa                                                    1999 aa                                               
  Functions                                                                 -- Member of yeast SWI/SNF                                                    -- Member of Brahma complex       -- Interaction with Brahma chromatin remodelling complex   -- Member of human swi/snf                            
  -- Antagonize wingless pathways                                           -- Co-factor of transcriptional activation by the steroid hormone receptors                                                                                                                                                      
                                                                                                                                                                                                                                                                                                             
  Name                                                                      nd                                                                            nd                                nd                                                         Osa2, held/Osa1, KIAA1235                             
                                                                                                                                                                                                                                                                                                             
  Accesion no                                                               ---                                                                           ---                               ---                                                        AF521671 and AF468300                                 
  Chromosome no                                                             ---                                                                           ---                               ---                                                        6q25.1--q25.3                                         
  cDNA Length                                                               ---                                                                           ---                               ---                                                        5482 pb                                               
  Protein Length                                                            ---                                                                           ---                               ---                                                        1740 aa                                               
  Functions                                                                 ---                                                                           ---                               ---                                                        -- Member of human swi/snf                            
  -- Promotes transcriptional activation by the steroid hormone receptors                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                             
  Subgroup 2                                                                Name                                                                          nd                                Dead Ringer (Dri)                                          Bright                                                DRIL-1
                                                                                                                                                                                                                                                                                                             
  Accesion no                                                               ---                                                                           U62542                            U60335                                                     U88047                                                
  Chromosome no                                                             ---                                                                           ---                               10                                                         19p13.3                                               
  cDNA Length                                                               ---                                                                           3696 bp                           4842 bp                                                    2725 pb                                               
  Protein Length                                                            ---                                                                           901 aa                            601 aa                                                     593 aa                                                
  Functions                                                                 ---                                                                           -- Embryo patterning              -- B-Cell activator                                        -- Binds the pRb controlled transcription             
  -- Target sequence: AGATT/ATAA                                            -- Target sequence: AGATTAA                                                   -- Target sequence: A/GATT/ATAA                                                                                                                    
                                                                                                                                                                                                                                                                                                             
  Name                                                                      nd                                                                            nd                                Mrf2                                                       Mrf2                                                  
                                                                                                                                                                                                                                                                                                             
  Accesion no                                                               ---                                                                           ---                               AF280065                                                   M733837 (partial sequence)                            
  Chromosome no                                                             ---                                                                           ---                               10                                                         10                                                    
  cDNA Length                                                               ---                                                                           ---                               3647 bp                                                    ---                                                   
  Protein Length                                                            ---                                                                           ---                               1188 aa                                                    ---                                                   
  Functions                                                                 ---                                                                           ---                               -- Accumulation of lipids in postnatal life                ---                                                   
  -- Target sequence: AATA(C/T)                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                             
  Name                                                                      nd                                                                            nd                                Jumonji                                                    Jumonji                                               
                                                                                                                                                                                                                                                                                                             
  Accesion no                                                               ---                                                                           ---                               BC05244                                                    U57592                                                
  Chromosome no                                                             ---                                                                           ---                               ---                                                        6q24.p23                                              
  cDNA Length                                                               ---                                                                           ---                               4939 bp                                                    ---                                                   
  Protein Length                                                            ---                                                                           ---                               1324 aa                                                    1266 aa                                               
  Functions                                                                 ---                                                                           ---                               -- Neural embryogenesis                                    Highly expressed by neuron cells during development   
  ------------------------------------------------------------------------- ----------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------- ----------------------------------------------------- ----------------------------

###### 

*List of antisens oligonucleotides directed against 6A3-5*. Sequence and position (on human homologous held/Osa2) of different ODN directed against 6A3-5. Only ODNAS3 showed significant effects on 6A3-5 expression. Scrambled ODN3 (ODN Scr3) and mismatched (ODN Mis3) as used to test sequence specificity of ODNAS3.

  ---------- ---------------------------------------------- -------------------
  Name       Sequence 5′--3′                                Position/AF468300
                                                            
  ODNAs1     agcttgtcgaacttactggct                          3870--3890
  ODNAs2     cagcttgtcgaacttactggctt                        3869--3889
  ODNAs3     tgggatctgccc[atg]{.ul}                         57--71
  ODN Scr3   agctcggttcacggt                                ---
  ODN Mis3   [a]{.ul}ggga[g]{.ul}ct[a]{.ul}ccc [c]{.ul}tg   57--71
  ODNAs4     tcacatctgagaatgg                               2245--2260
  ---------- ---------------------------------------------- -------------------
